stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Total debt
PTC Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $2.6B, up 9.03% from $2.4B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $2.8B. Over the past ten years it has ranged from $91.8M (fiscal 2015) to $2.6B (fiscal 2025) — the current reading is the highest in ten years. PTC Therapeutics, Inc. ranks 7th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $2.6B | 9.03% |
| FY2024 | $2.4B | 12.63% |
| FY2023 | $2.1B | 56.90% |
| FY2022 | $1.3B | 13.73% |
| FY2021 | $1.2B | 17.15% |
| FY2020 | $1.0B | 222.43% |
| FY2019 | $313.9M | 105.12% |
| FY2018 | $153.0M | 5.55% |
| FY2017 | $145.0M | 47.60% |
| FY2016 | $98.2M | 6.93% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $2.8B | (2.42%) |
| Jun 2026 | $2.9B | 11.41% |
| Mar 2026 | $2.6B | 0.62% |
| Dec 2025 | $2.6B | 9.06% |
| 41 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PTCT PTC Therapeutics, Inc. | $2.8B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $731.3M |
| COGT Cogent Biosciences, Inc. compare | $223.5M |
| SRRK Scholar Rock Holding Corporation compare | $196.2M |
| KOD Kodiak Sciences Inc. compare | $174.5M |
| CGON CG Oncology, Inc. compare | $3.0M |
| IMVT Immunovant, Inc. compare | $614.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| MANE Veradermics Incorporated compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement